Ultragenyx Pharmaceutical Inc. (RARE)

Market Cap	3.50B
Revenue (ttm)	560.23M
Net Income (ttm)	-569.18M
Shares Out	92.50M
EPS (ttm)	-6.29
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	323,146
Open	38.64
Previous Close	38.89
Day's Range	37.70 - 38.68
52-Week Range	36.71 - 60.37
Beta	0.67
Analysts	Strong Buy
Price Target	95.93 (+153.65%)
Earnings Date	May 1, 2025

About RARE

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jan 31, 2014
• Employees: 1,294
• Stock Exchange: NASDAQ
• Ticker Symbol: RARE
• Website: https://www.ultragenyx.com

Financial Performance

In 2024, Ultragenyx Pharmaceutical's revenue was $560.23 million, an increase of 29.01% compared to the previous year's $434.25 million. Losses were -$569.18 million, -6.17% less than in 2023.

Analyst Forecast

According to 15 analysts, the average rating for RARE stock is "Strong Buy." The 12-month stock price forecast is $95.93, which is an increase of 153.65% from the latest price.

Price Target

$95.93

(153.65% upside)

Analyst Consensus: Strong Buy